Influx Health.
Finavenue Growth Fund has slipped off the latest Influx Health shareholder list, indicating either a complete exit or a trim below the 1 percent reporting threshold from its previously disclosed 1.35 percent stake.
A healthcare-focused contract manufacturing company incorporated in September 2020, Influx Healthtech specializes in producing pharmaceutical products for partner companies across India. The firm operates in the contract manufacturing sector, providing comprehensive end-to-end production capabilities and quality assurance services to pharmaceutical clients. Its business model centers on offering reliable, scalable manufacturing services to established pharmaceutical brands seeking outsourced production capacity and operational efficiency.
Managed by A9 Finsight, with around Rs 360 cr AUM and a top-of-category track record (+233 percent absolute return since July 2023, +132 percent in CY2024 vs CNX Smallcap +24 percent). Allocates ~45 percent to SME listings, ~35 percent to mainboard companies and ~20 percent to pre-IPO. Run by Abhishek Jaiswal, among India's youngest fund managers.
